tradingkey.logo
tradingkey.logo

Standard BioTools Inc

LAB
View Detailed Chart
0.921USD
-0.037-3.84%
Market hours ETQuotes delayed by 15 min
18.88MMarket Cap
LossP/E TTM

Standard BioTools Inc

0.921
-0.037-3.84%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.84%

5 Days

-6.44%

1 Month

-18.48%

6 Months

-27.46%

Year to Date

-28.03%

1 Year

-19.19%

View Detailed Chart

Key Insights

Standard BioTools Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 86 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.55.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Standard BioTools Inc's Score

Industry at a Glance

Industry Ranking
86 / 208
Overall Ranking
213 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Standard BioTools Inc Highlights

StrengthsRisks
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Growing
The company is in a growing phase, with the latest annual income totaling USD 85.33M.
Undervalued
The company’s latest PE is -4.57, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 297.38M shares, decreasing 8.74% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 39.53K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.65.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
1.550
Target Price
+61.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Standard BioTools Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Standard BioTools Inc Info

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Ticker SymbolLAB
CompanyStandard BioTools Inc
CEOEgholm (Michael)
Websitehttps://www.standardbio.com/
KeyAI